


الجمهورية الجزائرية الديمقراطية الشعبية
وزارة التعليم العالي والبحث العلمي

Université Ferhat Abbas Sétif 1
Faculté des Sciences de la
Nature et de la Vie



جامعة فرحات عباس، سطيف 1
كلية علوم الطبيعة والحياة

N°...../SNV/2025

DEPARTMENT OF BIOCHEMISTRY

DISSERTATION

Presented by

RANIA MALEK BOUFEDJI

LEILA RIHAB CHAIBI

For obtaining the diploma of

MASTER

Field: Biological Science

Specialty: Immunology

THEME

PRETERM BIRTH

Publicly supported on:
28/06/2025

Before the jury:

DALILA MESSAOUDI

ZAHIRA HOUCHER

RIMA ALLOUNI

MCA UFA Sétif 1

MCB UFA Sétif 1

MCA UFA Sétif 1

President

Promoter

Examiner

2024/2025



Acknowledgements

First and foremost, we thank Allah, the Most Gracious and Most Merciful, for granting us the strength, patience, and perseverance to complete this work.

*We would like to express our deepest gratitude to our thesis advisor, **Dr. Zahira Houcher**, for her invaluable guidance, support, and continuous encouragement throughout this research journey. Her expertise and dedication were essential to the development and completion of this thesis.*

*Our sincere thanks go to **Dr. Messaoudi Dalila**, for her precious teaching and mentorship during the two years of our Master's program. Her knowledge and passion for the field have left a lasting impact on us.*

*We are also very grateful to **Dr. Allouni Rima**, for her time, constructive feedback, and kind consideration of our work.*

Dedication

I dedicate this work to the soul of my grandfather, Al-Arabi Chaibi, who played a part in the very first stage of my education and was the beginning of this great success.

I also dedicate this work to my beloved father, Chaibi Mohamed Lamine, my wonderful mother, Douar Yasmina, and my dear sisters, Widad and Alaa.

Thank you for your endless love, support, and for believing in me even when I doubted myself. Your presence has been a source of strength and support at every step of my journey.

And I dedicate this success to myself — proud of who I have become and grateful for every moment I never gave up.

To my partner, Rania, and my dearest friends—Nourhene, Nour El Imane, Abdelmanam, and Akram—thank you for making my university years unforgettable. This master's degree would not have been the same without you.

LEILA

Dedication

This thesis is dedicated to my dear parents, Boufedji L. Khaled and Radjah C. Malika. Thank you for your unwavering support in helping me reach my dreams. I hope accomplishing this milestone makes you as proud of me as I am proud to call you, my parents.

To my beloved sisters, Dina and Balkis—thank you for everything you've done for me. I am forever grateful to have you by my side.

To my dear grandfather, Boufedji Mustapha—may God protect and bless you.

To my soul sister, Bouchra, and my wonderful cousins—your love and encouragement have been at light in my life.

Thank you for being my pillars of strength.

To my partner, Leila, and my dearest friends—Nourhene, Nour El Imane, Abdelmanam, and Akram—thank you for making my college years unforgettable. This master's degree would not have been the same without you.



B.M. RANIA

Résumé

La naissance prématurée, définie comme l'accouchement avant 37 semaines de gestation, concerne environ 10 % des grossesses dans le monde et constitue une cause majeure de morbidité et de mortalité néonatale. La prématurité a des causes complexes et multifactorielles, y compris des déclencheurs directs, ainsi que des facteurs indirects. La dérégulation immunologique joue un rôle central dans la prématurité, notamment par l'activation prématurée des voies NF- κ B/MAPK médiées par les TLR, la production de cytokines et l'infiltration de cellules immunitaires, qui entraînent la contractilité utérine.

Des biomarqueurs non invasifs, biochimique et génétique tels que la fibronectine fœtale, des cytokines (par exemple IL-6 et CXCL8), Les longs ARN non codants (lncRNA), des microARNs (miRNA) et des métalloprotéinases matricielles, offrent des pistes prometteuses pour la prédiction précoce de la prématurité permettant les stratégies thérapeutiques ciblant l'inflammation, y compris les antagonistes TLR4, les inhibiteurs de chimiokines à large spectre, les agents suppresseurs de cytokines et les thérapies basées sur les microARN, de prévenir l'accouchement prématuré.

Mots clés : Naissance prématurée, nouveau-nés prématurés, travail prématuré, biomarqueurs, inflammation.

Abstract

Preterm birth, defined as delivery before 37 weeks' gestation, occurs in around 10% of pregnancies worldwide and is a major cause of neonatal morbidity and mortality. Prematurity has complex, multifactorial causes, including direct triggers as well as indirect factors. Immunological dysregulation plays a central role in prematurity, notably through premature activation of TLR-mediated NF- κ B/MAPK pathways, cytokine production and immune cell infiltration, which result in uterine contractility.

Non-invasive, biochemical and genetic biomarkers such as foetal fibronectin, cytokines (e.g. IL-6 and CXCL8), long non-coding RNAs (lncRNAs), microRNAs (miRNAs) and matrix metalloproteinases offer promising paths for early prediction of prematurity, enabling therapeutic strategies targeting inflammation, including TLR4 antagonists, broad-spectrum chemokine inhibitors, cytokine suppressive agents and microRNA-based therapies, to prevent preterm delivery.

Key words: Preterm birth, Premature newborns, Preterm labour, Biomarkers, inflammation

ملخص

تحدث الولادة المبكرة، التي تعرف بأنها الولادة قبل 37 أسبوعاً من الحمل، في حوالي 10% من حالات الحمل في جميع أنحاء العالم، وهي سبب رئيسي لاعتلال حديثي الولادة ووفياتهم. وللولادة المبكرة أسباب معقدة ومتعددة العوامل، بما في ذلك المسببات المباشرة والعوامل غير المباشرة. يلعب خلل التنظيم المناعي دوراً محورياً في الولادة المبكرة، لا سيما من خلال التنشيط المبكر لمسارات **NF-κB/MAPK** بواسطة **TLR**، وإنتاج السيتوكين وتسلسل الخلايا المناعية، والتي تدفع انقباض الرحم.

توفر المؤشرات الحيوية غير الجراحية البيوكيميائية والوراثية مثل الفيبرونيكتين الجنيني والسيتوكينات (مثل **IL-6** و **CXCL8**) والحمض النووي الريبي الطويل غير المشفر (**lncRNAs**) والحمض النووي الريبي المجهرى (**miRNAs**) و الميتالوبروتيناز توفر طرقاً واعدة للتنبؤ المبكر بالولادة المبكرة، مما يتيح استراتيجيات علاجية تستهدف الالتهاب، بما في ذلك مضادات **TLR4** ومثبطات الكيمياوكين واسعة الطيف والعوامل المثبطة للسيتوكين والعلاجات القائمة على الحمض النووي الريبي الميكروي لمنع الولادة المبكرة.

الكلمات المفتاحية: الولادة المبكرة، الأطفال حديثي الولادة المبتسرين، المخاض المبكر، المؤشرات الحيوية، الالتهاب.

Table Of Contents

Résumé.....	
Abstract.....	
ملخص.....	
List of figures	
List of abbreviations	
Introduction.....	1

Chapter I: Generalities on preterm birth

I. Preterm Birth.....	2
I.1. Definition	2
I.2. Subcategories of prematurity	2
I.2.1. Extremely preterm (between 22 and 28 weeks):.....	2
I.2.2. Very preterm (from 28 to 32 weeks):.....	2
I.2.3. Moderate preterm (from 32 to 34 weeks):.....	2
I.2.4. Late preterm (from 34 to 36 weeks):	2
I.3. Epidemiology	3
I.4. Types of prematurity	3
I.4.1. Spontaneous prematurity:	4
I.4.2. Induced prematurity:	4
I.5. Consequences of Prematurity on the infant	4
I.5.1. Short-term:.....	4
I.5.2. Long-term:	5

Chapter II: Causes and risk factors involved in the onset of PTB

I. Direct causes of prematurity	6
I.1. Inflammatory Process in the Uterus	6
I.2. Chronic maternal diseases	6
I.3. Cervical insufficiency	6
I.4. Genetic predisposition	6
I.5. Resistance to progesterone P4.....	7
II. Indirect causes of prematurity	7
II.1. Environmental toxin exposure.....	7
II.2. Psychosocial stress	7
II.3. Advanced maternal age	7

Chapter III: Inflammatory mechanisms of PTB

I. Immunological landscape of pregnancy	8
---	---

II.	Phases of parturition.....	9
III.	Inflammation and preterm birth	11
III.1.	The Activation and Upregulation of Inflammation	13
III.2.	Mediators.....	13
III.3.	Immune cells.....	14

Chapter IV: Biomarkers for the prediction of PTB

I.	Biomarkers for the prediction of PTB.....	16
I.1.	Biochemical biomarkers.....	16
I.1.2.	Foetal fibronectin.....	17
I.1.3.	Cytokines and chemokines.....	18
I.1.5.	Relaxin.....	20
I.1.6.	Lactate dehydrogenase.....	20
I.1.7.	Adrenocorticotrophic hormone.....	21
I.1.8.	Alpha-fetoprotein and human chorionic gonadotropin	21
I.1.9.	Ferritin and prolactin.....	22
I.1.10.	Placental protein 13.....	22
I.1.11.	Corticotropin-releasing hormone	22
I.1.12.	Matrix metalloproteinase enzymes	23
	Other biochemical biomarkers	24
I.2.	Genetic biomarkers and epigenetic factors contributing to labour	24
I.2.1.	Maternal genetic factors contributing to labour	25
I.2.2.	Foetal genetic factors contributing to labour	25
I.2.3.	MicroRNAs	26
I.2.4.	LncRNA.....	27
I.2.5.	DNA methylation.....	27
I.2.6.	Histone modification	28
I.2.7.	Genetic-based screening strategies for prediction of preterm birth	28

Chapter V: Emerging anti-inflammatory therapeutics to prevent PTB

I.	Emerging anti-inflammatory therapies.....	30
I.1.	Targeting toll-like receptor 4.....	30
I.2.	Targeting cytokines.....	32
I.3.	Targeting chemokines.....	34
I.4.	Treatments using miRNA in different pregnancy disorders	36
I.5.	Tocolytic agents.....	37
	Conclusion.....	39

Bibliographic references 33